Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not B
- PDF / 752,754 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 92 Downloads / 164 Views
ORIGINAL ARTICLE
Concomitant 5‑Aminosalicylate Therapy in Moderate‑to‑Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial Bhairavi Balram1 · Harshad Joshi1 · Karen Wong1 · Karen I. Kroeker1 · Levinus A. Dieleman1 · Brendan P. Halloran1 · Daniel C. Baumgart1 · Farhad Peerani1 Received: 22 July 2020 / Accepted: 30 October 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Background and Aims While there is recent literature to support the discontinuation of 5-aminosalicylate (5-ASA) upon the initiation of biologics, continuing 5-ASA after treatment failure is relatively common. We aimed to assess the impact of concomitant 5-ASA therapy on clinical outcomes in ulcerative colitis (UC) patients escalated to infliximab. Methods This is a retrospective chart review of patients with moderate-to-severe UC started on infliximab between January 2012 and December 2017 at the University of Alberta. The primary outcome was clinical remission (partial Mayo score
Data Loading...
